BBK Worldwide^® Blog

The clinical trial landscape saw a lot of changes in 2021, from decentralized clinical trial adoption to a greater emphasis on diversity and inclusion. But what’s in store for 2022? We asked our industry experts to weigh in with their predictions.

Earlier this week, BBK's Senior Director of Patient Engagement Services Mike Johnson spoke with Outsourcing-Pharma to discuss the RSG^® Arrive travel program and its recent milestone of 20,000 completed trips.

In this in-depth interview, Mike discusses what sets this program apart from others as he highlights the concierge specialists who are experienced in understanding all the ramifications of a request, as it relates not only to arranging a travel itinerary but also ensuring the itinerary supports patient health, safety, and compliance. In addition, Mike shares insight into the significance of the milestone for BBK as well as the industry at large. Click here to read the full article.

RSG® Arrive Reaches Milestone of 20,000 Completed Trips

Enrollment, Engagement, and Satisfaction Data Confirms That Extending Study Support Beyond the Care Setting Yields Positive Results

Launched in 2012, RSG® Arrive has made clinical trial participation possible for thousands of patients worldwide. Today, the program has reached a major milestone with the completion of 20,000 trips. 

We recently sat down with BBK’s Director of RSG Services Mike Johnson to discuss how clinical trial patient travel has been impacted by COVID-19 and how BBK's travel program RSG® Arrive has responded.